Guangdong Biolight Meditech Co Ltd (300246) — Strategic Asset Allocation Index
Guangdong Biolight Meditech Co Ltd (300246) has a Strategic Asset Allocation Index of 49.6% as of March 2023. Strategic assets (PP&E of CN¥761.97 Million plus long-term investments of CN¥-) total CN¥761.97 Million, measured against net assets of CN¥1.54 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See net asset quality index of Guangdong Biolight Meditech Co Ltd to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Guangdong Biolight Meditech Co Ltd Strategic Asset Allocation Index (2008–2022)
This chart shows how Guangdong Biolight Meditech Co Ltd's Strategic Asset Allocation Index has evolved across 15 annual periods from 2008 to 2022. As of March 2023, the index stands at 49.6%, representing strategic assets of CN¥761.97 Million against net assets of CN¥1.54 Billion CNY. For live market cap and overall valuation, see market cap of Guangdong Biolight Meditech Co Ltd.
Annual Strategic Asset Allocation Index for Guangdong Biolight Meditech Co Ltd (2008–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Guangdong Biolight Meditech Co Ltd from 2008 to 2022, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Guangdong Biolight Meditech Co Ltd (300246) net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 49.1% | CN¥737.85 Million | CN¥737.85 Million | CN¥- | CN¥1.50 Billion | ▼ -9.8 pp |
| 2021 | 58.9% | CN¥584.72 Million | CN¥584.72 Million | CN¥- | CN¥992.38 Million | ▲ +16.1 pp |
| 2020 | 42.8% | CN¥442.18 Million | CN¥442.18 Million | CN¥- | CN¥1.03 Billion | ▲ +3.5 pp |
| 2019 | 39.3% | CN¥230.10 Million | CN¥230.10 Million | CN¥- | CN¥585.84 Million | ▲ +6.0 pp |
| 2018 | 33.3% | CN¥206.88 Million | CN¥204.78 Million | CN¥2.10 Million | CN¥622.19 Million | ▲ +5.1 pp |
| 2017 | 28.1% | CN¥155.78 Million | CN¥153.66 Million | CN¥2.12 Million | CN¥554.08 Million | ▲ +5.0 pp |
| 2016 | 23.1% | CN¥116.44 Million | CN¥114.44 Million | CN¥2.00 Million | CN¥504.27 Million | ▲ +3.3 pp |
| 2015 | 19.8% | CN¥91.40 Million | CN¥91.40 Million | CN¥- | CN¥460.87 Million | ▲ +0.3 pp |
| 2014 | 19.6% | CN¥83.74 Million | CN¥83.74 Million | CN¥- | CN¥427.94 Million | ▼ -3.0 pp |
| 2013 | 22.5% | CN¥88.82 Million | CN¥88.82 Million | CN¥- | CN¥393.88 Million | ▲ +10.2 pp |
| 2012 | 12.4% | CN¥46.75 Million | CN¥46.75 Million | CN¥- | CN¥377.93 Million | ▲ +5.0 pp |
| 2011 | 7.3% | CN¥26.00 Million | CN¥26.00 Million | CN¥- | CN¥354.32 Million | ▼ -13.1 pp |
| 2010 | 20.5% | CN¥18.40 Million | CN¥18.40 Million | CN¥- | CN¥89.93 Million | ▼ -2.8 pp |
| 2009 | 23.3% | CN¥15.59 Million | CN¥15.59 Million | CN¥- | CN¥66.94 Million | ▼ -6.0 pp |
| 2008 | 29.3% | CN¥13.62 Million | CN¥13.62 Million | CN¥- | CN¥46.53 Million | — |